NEULANDLABNeuland Laboratories Limited
Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-07-20 (delayed ~30 min in market hours)
₹18,949.00
▲ 2.79%Strong
Price & Volume
Loading chart…
Key Ratios
Market Cap (₹ cr)24,311.40
P/E66.75
P/B12.97
PEG0.10
ROE %19.40
ROCE %22.50
Debt / Equity0.16
EPS283.88
Revenue Growth %136.40
Profit Growth %664.40
Dividend Yield %0.00
Promoter Holding %37.76
FII Holding %28.17
DII Holding %—
Beta-0.32
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
| Pullback to 21-EMA | LONG | 76% | ₹18,949.00 | ₹18,055.00 | ₹20,983.00 | 2.28 |
BUYConviction 76%
Why buy
- • Revenue growth: 136.4% YoY
- • Profit growth: 664.4% YoY
- • ROE: 19.4%
- • RSI: 59
- • Price vs EMA21: above
- • Price vs SMA50: above
- • Pullback to 21-EMA signal (setup quality 76%)
Bull case
- • Revenue growth: 136.4% YoY
- • Profit growth: 664.4% YoY
- • ROE: 19.4%
- • RSI: 59
Bear case
- • Valuation vs sector: P/E 66.8 vs sector 38.6
- • Dividend yield: 0.00%
- • MACD: bearish
- • Volume: 0.6x 20-day average
Key risks
- • Elevated volatility / drawdown profile — size positions accordingly
- • Valuation vs sector: P/E 66.8 vs sector 38.6
- • Dividend yield: 0.00%
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Entry (CMP)
₹18,949.00
Stop Loss
₹17,427.22
risk 8%
Target 1 (1.5R)
₹21,231.66
+12.0%
Target 2 (3R)
₹23,514.33
+24.1%
Support (20d)
₹17,254.00
Resistance (52w)
₹20,089.00
Risk : Reward
1 : 1.5 → 1 : 3
risking ₹1,521.78/share
ATR (volatility)
₹608.71
avg daily range
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹608.71). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.
Score Breakdown
Fundamental
78
Technical
68
Momentum
85
Risk (safety)
45